Adlai Nortye Ltd
N2U0
Company Profile
Business description
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Contact
685 US Highway 1
New Jersey Biotechnology Development Center, 2nd floor
North BrunswickNJ08902
USAT: +1 848 230-7430
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
123
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,184.20 | 27.30 | -0.30% |
| CAC 40 | 8,314.92 | 16.04 | -0.19% |
| DAX 40 | 25,286.29 | 0.05 | 0.00% |
| Dow JONES (US) | 49,149.63 | 42.36 | -0.09% |
| FTSE 100 | 10,233.61 | 49.26 | 0.48% |
| HKSE | 26,923.62 | 76.19 | -0.28% |
| NASDAQ | 23,471.75 | 238.13 | -1.00% |
| Nikkei 225 | 54,110.50 | 230.73 | -0.42% |
| NZX 50 Index | 13,659.79 | 97.92 | -0.71% |
| S&P 500 | 6,926.60 | 37.14 | -0.53% |
| S&P/ASX 200 | 8,861.70 | 19.30 | -0.22% |
| SSE Composite Index | 4,112.60 | 13.49 | -0.33% |